Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

USP14 inhibition corrects an in vivo model of impaired mitophagy.

Chakraborty J, von Stockum S, Marchesan E, Caicci F, Ferrari V, Rakovic A, Klein C, Antonini A, Bubacco L, Ziviani E.

EMBO Mol Med. 2018 Sep 24. pii: e9014. doi: 10.15252/emmm.201809014. [Epub ahead of print]

2.

Superoxide Radical Dismutation as New Therapeutic Strategy in Parkinson's Disease.

De Lazzari F, Bubacco L, Whitworth AJ, Bisaglia M.

Aging Dis. 2018 Aug 1;9(4):716-728. doi: 10.14336/AD.2017.1018. eCollection 2018 Aug. Review.

3.

Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease.

Faustini G, Longhena F, Varanita T, Bubacco L, Pizzi M, Missale C, Benfenati F, Björklund A, Spano P, Bellucci A.

Acta Neuropathol. 2018 Oct;136(4):621-639. doi: 10.1007/s00401-018-1892-1. Epub 2018 Jul 25.

PMID:
30046897
4.

Dopamine Oxidation Products as Mitochondrial Endotoxins, a Potential Molecular Mechanism for Preferential Neurodegeneration in Parkinson's Disease.

Biosa A, Arduini I, Soriano ME, Giorgio V, Bernardi P, Bisaglia M, Bubacco L.

ACS Chem Neurosci. 2018 Jul 3. doi: 10.1021/acschemneuro.8b00276. [Epub ahead of print]

PMID:
29906101
5.

Impacts of increased α-synuclein on clathrin-mediated endocytosis at synapses: implications for neurodegenerative diseases.

Medeiros AT, Bubacco L, Morgan JR.

Neural Regen Res. 2018 Apr;13(4):647-648. doi: 10.4103/1673-5374.230289. No abstract available.

6.

Diabetes Mellitus as a Risk Factor for Parkinson's Disease: a Molecular Point of View.

Biosa A, Outeiro TF, Bubacco L, Bisaglia M.

Mol Neurobiol. 2018 Nov;55(11):8754-8763. doi: 10.1007/s12035-018-1025-9. Epub 2018 Mar 28. Review.

PMID:
29594935
7.

Superoxide dismutating molecules rescue the toxic effects of PINK1 and parkin loss.

Biosa A, Sanchez-Martinez A, Filograna R, Terriente-Felix A, Alam SM, Beltramini M, Bubacco L, Bisaglia M, Whitworth AJ.

Hum Mol Genet. 2018 May 1;27(9):1618-1629. doi: 10.1093/hmg/ddy069.

8.

Synapsin III is a key component of α-synuclein fibrils in Lewy bodies of PD brains.

Longhena F, Faustini G, Varanita T, Zaltieri M, Porrini V, Tessari I, Poliani PL, Missale C, Borroni B, Padovani A, Bubacco L, Pizzi M, Spano P, Bellucci A.

Brain Pathol. 2018 Jan 13. doi: 10.1111/bpa.12587. [Epub ahead of print]

PMID:
29330884
9.

α-Synuclein Dimers Impair Vesicle Fission during Clathrin-Mediated Synaptic Vesicle Recycling.

Medeiros AT, Soll LG, Tessari I, Bubacco L, Morgan JR.

Front Cell Neurosci. 2017 Dec 11;11:388. doi: 10.3389/fncel.2017.00388. eCollection 2017.

10.

PAK6 Phosphorylates 14-3-3γ to Regulate Steady State Phosphorylation of LRRK2.

Civiero L, Cogo S, Kiekens A, Morganti C, Tessari I, Lobbestael E, Baekelandt V, Taymans JM, Chartier-Harlin MC, Franchin C, Arrigoni G, Lewis PA, Piccoli G, Bubacco L, Cookson MR, Pinton P, Greggio E.

Front Mol Neurosci. 2017 Dec 14;10:417. doi: 10.3389/fnmol.2017.00417. eCollection 2017.

11.

High-Pressure-Driven Reversible Dissociation of α-Synuclein Fibrils Reveals Structural Hierarchy.

Piccirilli F, Plotegher N, Ortore MG, Tessari I, Brucale M, Spinozzi F, Beltramini M, Mariani P, Militello V, Lupi S, Perucchi A, Bubacco L.

Biophys J. 2017 Oct 17;113(8):1685-1696. doi: 10.1016/j.bpj.2017.08.042.

12.

Recent findings on the physiological function of DJ-1: Beyond Parkinson's disease.

Biosa A, Sandrelli F, Beltramini M, Greggio E, Bubacco L, Bisaglia M.

Neurobiol Dis. 2017 Dec;108:65-72. doi: 10.1016/j.nbd.2017.08.005. Epub 2017 Aug 18. Review.

PMID:
28823929
13.

Pressure effects on α-synuclein amyloid fibrils: An experimental investigation on their dissociation and reversible nature.

Piccirilli F, Plotegher N, Spinozzi F, Bubacco L, Mariani P, Beltramini M, Tessari I, Militello V, Perucchi A, Amenitsch H, Baldassarri E Jr, Steinhart M, Lupi S, Ortore MG.

Arch Biochem Biophys. 2017 Aug 1;627:46-55. doi: 10.1016/j.abb.2017.06.007. Epub 2017 Jun 15.

PMID:
28624352
14.

GTP binding regulates cellular localization of Parkinson's disease-associated LRRK2.

Blanca Ramírez M, Lara Ordóñez AJ, Fdez E, Madero-Pérez J, Gonnelli A, Drouyer M, Chartier-Harlin MC, Taymans JM, Bubacco L, Greggio E, Hilfiker S.

Hum Mol Genet. 2017 Jul 15;26(14):2747-2767. doi: 10.1093/hmg/ddx161.

15.

Molecular Insights and Functional Implication of LRRK2 Dimerization.

Civiero L, Russo I, Bubacco L, Greggio E.

Adv Neurobiol. 2017;14:107-121. doi: 10.1007/978-3-319-49969-7_6. Review.

PMID:
28353281
16.

Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.

Longo F, Mercatelli D, Novello S, Arcuri L, Brugnoli A, Vincenzi F, Russo I, Berti G, Mabrouk OS, Kennedy RT, Shimshek DR, Varani K, Bubacco L, Greggio E, Morari M.

Acta Neuropathol Commun. 2017 Mar 14;5(1):22. doi: 10.1186/s40478-017-0426-8.

17.

Synthesis, Structure Characterization, and Evaluation in Microglia Cultures of Neuromelanin Analogues Suitable for Modeling Parkinson's Disease.

Ferrari E, Capucciati A, Prada I, Zucca FA, D'Arrigo G, Pontiroli D, Bridelli MG, Sturini M, Bubacco L, Monzani E, Verderio C, Zecca L, Casella L.

ACS Chem Neurosci. 2017 Mar 15;8(3):501-512. doi: 10.1021/acschemneuro.6b00231. Epub 2016 Nov 28.

PMID:
28292181
18.

Cross-talk between LRRK2 and PKA: implication for Parkinson's disease?

Greggio E, Bubacco L, Russo I.

Biochem Soc Trans. 2017 Feb 8;45(1):261-267. doi: 10.1042/BST20160396. Review.

PMID:
28202680
19.

2-Hydroxypyridine-N-oxide-Embedded Aurones as Potent Human Tyrosinase Inhibitors.

Haudecoeur R, Carotti M, Gouron A, Maresca M, Buitrago E, Hardré R, Bergantino E, Jamet H, Belle C, Réglier M, Bubacco L, Boumendjel A.

ACS Med Chem Lett. 2016 Nov 17;8(1):55-60. doi: 10.1021/acsmedchemlett.6b00369. eCollection 2017 Jan 12.

20.

DOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function.

Plotegher N, Berti G, Ferrari E, Tessari I, Zanetti M, Lunelli L, Greggio E, Bisaglia M, Veronesi M, Girotto S, Dalla Serra M, Perego C, Casella L, Bubacco L.

Sci Rep. 2017 Jan 13;7:40699. doi: 10.1038/srep40699.

21.

α-Synuclein is a Novel Microtubule Dynamase.

Cartelli D, Aliverti A, Barbiroli A, Santambrogio C, Ragg EM, Casagrande FV, Cantele F, Beltramone S, Marangon J, De Gregorio C, Pandini V, Emanuele M, Chieregatti E, Pieraccini S, Holmqvist S, Bubacco L, Roybon L, Pezzoli G, Grandori R, Arnal I, Cappelletti G.

Sci Rep. 2016 Sep 15;6:33289. doi: 10.1038/srep33289.

22.

LRRK2 deficiency impacts ceramide metabolism in brain.

Ferrazza R, Cogo S, Melrose H, Bubacco L, Greggio E, Guella G, Civiero L, Plotegher N.

Biochem Biophys Res Commun. 2016 Sep 23;478(3):1141-6. doi: 10.1016/j.bbrc.2016.08.082. Epub 2016 Aug 15.

PMID:
27539321
23.

Erratum to: Leucine-rich repeat kinase 2 positively regulates inflammation and down-regulates NF-κB p50 signaling in cultured microglia cells.

Russo I, Berti G, Plotegher N, Bernardo G, Filograna R, Bubacco L, Greggio E.

J Neuroinflammation. 2016 Apr 1;13(1):70. doi: 10.1186/s12974-016-0535-5. No abstract available.

24.

Superoxide Dismutase (SOD)-mimetic M40403 Is Protective in Cell and Fly Models of Paraquat Toxicity: IMPLICATIONS FOR PARKINSON DISEASE.

Filograna R, Godena VK, Sanchez-Martinez A, Ferrari E, Casella L, Beltramini M, Bubacco L, Whitworth AJ, Bisaglia M.

J Biol Chem. 2016 Apr 22;291(17):9257-67. doi: 10.1074/jbc.M115.708057. Epub 2016 Mar 7.

25.

Are Human Tyrosinase and Related Proteins Suitable Targets for Melanoma Therapy?

Buitrago E, Hardré R, Haudecoeur R, Jamet H, Belle C, Boumendjel A, Bubacco L, Réglier M.

Curr Top Med Chem. 2016;16(27):3033-3047. Review.

PMID:
26881706
26.

LRRK2 phosphorylates pre-synaptic N-ethylmaleimide sensitive fusion (NSF) protein enhancing its ATPase activity and SNARE complex disassembling rate.

Belluzzi E, Gonnelli A, Cirnaru MD, Marte A, Plotegher N, Russo I, Civiero L, Cogo S, Carrion MP, Franchin C, Arrigoni G, Beltramini M, Bubacco L, Onofri F, Piccoli G, Greggio E.

Mol Neurodegener. 2016 Jan 13;11:1. doi: 10.1186/s13024-015-0066-z.

27.

Lysines, Achilles' heel in alpha-synuclein conversion to a deadly neuronal endotoxin.

Plotegher N, Bubacco L.

Ageing Res Rev. 2016 Mar;26:62-71. doi: 10.1016/j.arr.2015.12.002. Epub 2015 Dec 9. Review.

PMID:
26690800
28.

Leucine-rich repeat kinase 2 positively regulates inflammation and down-regulates NF-κB p50 signaling in cultured microglia cells.

Russo I, Berti G, Plotegher N, Bernardo G, Filograna R, Bubacco L, Greggio E.

J Neuroinflammation. 2015 Dec 9;12:230. doi: 10.1186/s12974-015-0449-7. Erratum in: J Neuroinflammation. 2016;13(1):70.

29.

Anti-Oxidants in Parkinson's Disease Therapy: A Critical Point of View.

Filograna R, Beltramini M, Bubacco L, Bisaglia M.

Curr Neuropharmacol. 2016;14(3):260-71. Review.

30.

The functional dissection of the plasma corona of SiO₂-NPs spots histidine rich glycoprotein as a major player able to hamper nanoparticle capture by macrophages.

Fedeli C, Segat D, Tavano R, Bubacco L, De Franceschi G, de Laureto PP, Lubian E, Selvestrel F, Mancin F, Papini E.

Nanoscale. 2015 Nov 14;7(42):17710-28. doi: 10.1039/c5nr05290d.

PMID:
26451907
31.

Leucine-rich repeat kinase 2 interacts with p21-activated kinase 6 to control neurite complexity in mammalian brain.

Civiero L, Cirnaru MD, Beilina A, Rodella U, Russo I, Belluzzi E, Lobbestael E, Reyniers L, Hondhamuni G, Lewis PA, Van den Haute C, Baekelandt V, Bandopadhyay R, Bubacco L, Piccoli G, Cookson MR, Taymans JM, Greggio E.

J Neurochem. 2015 Dec;135(6):1242-56. doi: 10.1111/jnc.13369. Epub 2015 Oct 19.

32.

Analysis of the Catecholaminergic Phenotype in Human SH-SY5Y and BE(2)-M17 Neuroblastoma Cell Lines upon Differentiation.

Filograna R, Civiero L, Ferrari V, Codolo G, Greggio E, Bubacco L, Beltramini M, Bisaglia M.

PLoS One. 2015 Aug 28;10(8):e0136769. doi: 10.1371/journal.pone.0136769. eCollection 2015.

33.

Effects of Trehalose on Thermodynamic Properties of Alpha-synuclein Revealed through Synchrotron Radiation Circular Dichroism.

Ruzza P, Hussain R, Biondi B, Calderan A, Tessari I, Bubacco L, Siligardi G.

Biomolecules. 2015 May 4;5(2):724-34. doi: 10.3390/biom5020724.

34.

NADH fluorescence lifetime is an endogenous reporter of α-synuclein aggregation in live cells.

Plotegher N, Stringari C, Jahid S, Veronesi M, Girotto S, Gratton E, Bubacco L.

FASEB J. 2015 Jun;29(6):2484-94. doi: 10.1096/fj.14-260281. Epub 2015 Feb 24.

35.

Binding Interactions of Agents That Alter α-Synuclein Aggregation.

Sivanesam K, Byrne A, Bisaglia M, Bubacco L, Andersen N.

RSC Adv. 2015;5(15):11577-11590.

36.

Peptides as modulators of α-synuclein aggregation.

Ruzza P, Gazziero M, Marchi MD, Massalongo G, Marchiani A, Autiero I, Tessari I, Bubacco L, Calderan A.

Protein Pept Lett. 2015;22(4):354-61.

PMID:
25666040
37.

Differences in the binding of copper(I) to α- and β-synuclein.

De Ricco R, Valensin D, Dell'Acqua S, Casella L, Gaggelli E, Valensin G, Bubacco L, Mangani S.

Inorg Chem. 2015 Jan 5;54(1):265-72. doi: 10.1021/ic502407w. Epub 2014 Dec 12.

PMID:
25495902
38.

Human tyrosinase produced in insect cells: a landmark for the screening of new drugs addressing its activity.

Fogal S, Carotti M, Giaretta L, Lanciai F, Nogara L, Bubacco L, Bergantino E.

Mol Biotechnol. 2015 Jan;57(1):45-57. doi: 10.1007/s12033-014-9800-y.

PMID:
25189462
39.

A novel prion protein-tyrosine hydroxylase interaction.

Vicario M, Zagari A, Granata V, Munari F, Mammi S, Bubacco L, Skaper SD, Negro A.

CNS Neurol Disord Drug Targets. 2014;13(5):896-908. Review.

PMID:
25012618
40.

LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex.

Cirnaru MD, Marte A, Belluzzi E, Russo I, Gabrielli M, Longo F, Arcuri L, Murru L, Bubacco L, Matteoli M, Fedele E, Sala C, Passafaro M, Morari M, Greggio E, Onofri F, Piccoli G.

Front Mol Neurosci. 2014 May 27;7:49. doi: 10.3389/fnmol.2014.00049. eCollection 2014.

41.

The chaperone-like protein 14-3-3η interacts with human α-synuclein aggregation intermediates rerouting the amyloidogenic pathway and reducing α-synuclein cellular toxicity.

Plotegher N, Kumar D, Tessari I, Brucale M, Munari F, Tosatto L, Belluzzi E, Greggio E, Bisaglia M, Capaldi S, Aioanei D, Mammi S, Monaco HL, Samo B, Bubacco L.

Hum Mol Genet. 2014 Nov 1;23(21):5615-29. doi: 10.1093/hmg/ddu275. Epub 2014 Jun 3.

PMID:
24895406
42.

Investigation of binding-site homology between mushroom and bacterial tyrosinases by using aurones as effectors.

Haudecoeur R, Gouron A, Dubois C, Jamet H, Lightbody M, Hardré R, Milet A, Bergantino E, Bubacco L, Belle C, Réglier M, Boumendjel A.

Chembiochem. 2014 Jun 16;15(9):1325-33. doi: 10.1002/cbic.201402003. Epub 2014 May 21.

PMID:
24849818
43.

LRRK2 and neuroinflammation: partners in crime in Parkinson's disease?

Russo I, Bubacco L, Greggio E.

J Neuroinflammation. 2014 Mar 21;11:52. doi: 10.1186/1742-2094-11-52. Review.

44.

DJ-1 is a copper chaperone acting on SOD1 activation.

Girotto S, Cendron L, Bisaglia M, Tessari I, Mammi S, Zanotti G, Bubacco L.

J Biol Chem. 2014 Apr 11;289(15):10887-99. doi: 10.1074/jbc.M113.535112. Epub 2014 Feb 24.

45.

Number and Brightness analysis of alpha-synuclein oligomerization and the associated mitochondrial morphology alterations in live cells.

Plotegher N, Gratton E, Bubacco L.

Biochim Biophys Acta. 2014 Jun;1840(6):2014-24. doi: 10.1016/j.bbagen.2014.02.013. Epub 2014 Feb 20.

46.

Biophysical groundwork as a hinge to unravel the biology of α-synuclein aggregation and toxicity.

Plotegher N, Greggio E, Bisaglia M, Bubacco L.

Q Rev Biophys. 2014 Feb;47(1):1-48. doi: 10.1017/S0033583513000097. Epub 2014 Jan 21. Review.

PMID:
24443929
47.

Are dopamine derivatives implicated in the pathogenesis of Parkinson's disease?

Bisaglia M, Filograna R, Beltramini M, Bubacco L.

Ageing Res Rev. 2014 Jan;13:107-14. doi: 10.1016/j.arr.2013.12.009. Epub 2014 Jan 3. Review.

PMID:
24389159
48.

α-Synuclein oligomers induced by docosahexaenoic acid affect membrane integrity.

Fecchio C, De Franceschi G, Relini A, Greggio E, Dalla Serra M, Bubacco L, Polverino de Laureto P.

PLoS One. 2013 Nov 29;8(11):e82732. doi: 10.1371/journal.pone.0082732. eCollection 2013.

49.

Probing kojic acid binding to tyrosinase enzyme: insights from a model complex and QM/MM calculations.

Bochot C, Gouron A, Bubacco L, Milet A, Philouze C, Réglier M, Serratrice G, Jamet H, Belle C.

Chem Commun (Camb). 2014 Jan 11;50(3):308-10. doi: 10.1039/c3cc47469k. Epub 2013 Nov 14.

PMID:
24225561
50.

Ceftriaxone blocks the polymerization of α-synuclein and exerts neuroprotective effects in vitro.

Ruzza P, Siligardi G, Hussain R, Marchiani A, Islami M, Bubacco L, Delogu G, Fabbri D, Dettori MA, Sechi M, Pala N, Spissu Y, Migheli R, Serra PA, Sechi G.

ACS Chem Neurosci. 2014 Jan 15;5(1):30-8. doi: 10.1021/cn400149k. Epub 2013 Oct 24.

Supplemental Content

Loading ...
Support Center